Deborah Christensen, RN, BSN, HNB-BC
Intermountain Southwest Cancer CenterSt. George, UT
Authored Items
Cheryl Bellomo, MSN, RN, HON-ONN-CG, OCN, Deborah Christensen, RN, BSN, HNB-BC, Tricia Strusowski, RN, MS
April 19, 2016 | Articles & White Papers | Breast Cancer, Evidence into Practice
Along with the diagnosis of breast cancer comes many decisions regarding treatment options. Oncotype DX, a genomic/gene expression assay, provides quantitative assessment of chemotherapy benefit and risk of distant recurrence in early-stage estrogen receptor–positive (ER+), HER2/neu-negative breast cancer to assist in developing individualized treatment plans.
Last modified: March 10, 2021
